Cargando…

Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes

BACKGROUND: The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients’ health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients’ HRQoL data, should have established conte...

Descripción completa

Detalles Bibliográficos
Autores principales: Trudeau, Jeremiah J., He, Jianming, Rose, Esther, Panter, Charlotte, Randhawa, Sharan, Gater, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450032/
https://www.ncbi.nlm.nih.gov/pubmed/32851569
http://dx.doi.org/10.1186/s41687-020-00235-4
_version_ 1783574739099320320
author Trudeau, Jeremiah J.
He, Jianming
Rose, Esther
Panter, Charlotte
Randhawa, Sharan
Gater, Adam
author_facet Trudeau, Jeremiah J.
He, Jianming
Rose, Esther
Panter, Charlotte
Randhawa, Sharan
Gater, Adam
author_sort Trudeau, Jeremiah J.
collection PubMed
description BACKGROUND: The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients’ health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients’ HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible. The present study was conducted to evaluate the content validity of the Quality of Life in Myelodysplasia Scale (QUALMS) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An) PRO instruments in patients with lower-risk MDS. METHODS: In this cross-sectional, qualitative study, 16 patients aged ≥18 years with lower-risk MDS, who were RBC transfusion dependent, literate and fluent in US-English were interviewed. Interviews were semi-structured comprising of two parts: concept elicitation (CE) explored symptoms and impacts important to patients, and cognitive debriefing (CD) assessed understanding and relevance of the QUALMS and FACT-An. A conceptual model was developed, which was used to map the concepts that emerged during CE onto the QUALMS and FACT-An to assess concept coverage and suitability of the instruments. RESULTS: The median age of participants was 67.5 years (range: 51–91), with half being female (n = 8). Nine (56.2%) participants had intermediate-1-risk MDS and 10 (62.5%) were relapsed or refractory to erythropoiesis-stimulating agent treatment. Fatigue/tiredness (100.0%), shortness of breath (87.5%), weakness (81.2%), and low energy (75.0%) were reported most commonly and were the most bothersome symptoms as well. Of seven high-level HRQoL domains identified, activities of daily living (n = 16, 100.0%), physical functioning (n = 15, 93.8%), emotional wellbeing (n = 13, 81.3%), social functioning (n = 12, 75.0%), sleep disturbance (n = 9, 56.3%), and impact on work (n = 9, 56.3%) were the most commonly reported. For CD, the QUALMS and FACT-An were found to be mostly relevant and very well understood; response options were easy to use, and recall period was appropriate. CONCLUSION: Both QUALMS and FACT-An demonstrated a strong face and content validity in patients with lower-risk MDS, suggesting that these instruments are appropriate for assessing HRQoL in this population.
format Online
Article
Text
id pubmed-7450032
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74500322020-09-03 Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes Trudeau, Jeremiah J. He, Jianming Rose, Esther Panter, Charlotte Randhawa, Sharan Gater, Adam J Patient Rep Outcomes Research BACKGROUND: The lower-risk (low and intermediate-1 risk based on IPSS) myelodysplastic syndrome (MDS) has a negative impact on patients’ health-related quality of life (HRQoL). Patient Reported Outcomes (PROs) instruments, which are used to collect patients’ HRQoL data, should have established content validity in the target population to ensure that the instrument is comprehensive and comprehensible. The present study was conducted to evaluate the content validity of the Quality of Life in Myelodysplasia Scale (QUALMS) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An) PRO instruments in patients with lower-risk MDS. METHODS: In this cross-sectional, qualitative study, 16 patients aged ≥18 years with lower-risk MDS, who were RBC transfusion dependent, literate and fluent in US-English were interviewed. Interviews were semi-structured comprising of two parts: concept elicitation (CE) explored symptoms and impacts important to patients, and cognitive debriefing (CD) assessed understanding and relevance of the QUALMS and FACT-An. A conceptual model was developed, which was used to map the concepts that emerged during CE onto the QUALMS and FACT-An to assess concept coverage and suitability of the instruments. RESULTS: The median age of participants was 67.5 years (range: 51–91), with half being female (n = 8). Nine (56.2%) participants had intermediate-1-risk MDS and 10 (62.5%) were relapsed or refractory to erythropoiesis-stimulating agent treatment. Fatigue/tiredness (100.0%), shortness of breath (87.5%), weakness (81.2%), and low energy (75.0%) were reported most commonly and were the most bothersome symptoms as well. Of seven high-level HRQoL domains identified, activities of daily living (n = 16, 100.0%), physical functioning (n = 15, 93.8%), emotional wellbeing (n = 13, 81.3%), social functioning (n = 12, 75.0%), sleep disturbance (n = 9, 56.3%), and impact on work (n = 9, 56.3%) were the most commonly reported. For CD, the QUALMS and FACT-An were found to be mostly relevant and very well understood; response options were easy to use, and recall period was appropriate. CONCLUSION: Both QUALMS and FACT-An demonstrated a strong face and content validity in patients with lower-risk MDS, suggesting that these instruments are appropriate for assessing HRQoL in this population. Springer International Publishing 2020-08-26 /pmc/articles/PMC7450032/ /pubmed/32851569 http://dx.doi.org/10.1186/s41687-020-00235-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Trudeau, Jeremiah J.
He, Jianming
Rose, Esther
Panter, Charlotte
Randhawa, Sharan
Gater, Adam
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_full Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_fullStr Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_full_unstemmed Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_short Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
title_sort content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450032/
https://www.ncbi.nlm.nih.gov/pubmed/32851569
http://dx.doi.org/10.1186/s41687-020-00235-4
work_keys_str_mv AT trudeaujeremiahj contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT hejianming contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT roseesther contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT pantercharlotte contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT randhawasharan contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes
AT gateradam contentvalidityofpatientreportedoutcomesforuseinlowerriskmyelodysplasticsyndromes